Brain-derived neurotrophic factor (BDNF) modulates glutamatergic excitatory transmission in hippocampal primary cultures by acting at a presynaptic locus. Although it has been suggested that BDNF also modulates adult hippocampus glutamatergic transmission, this remains a matter of controversy. To clarify a putative role for this neurotrophin in the modulation of glutamate release we applied exogenous BDNF to isolated adult rat hippocampal nerve terminals. BDNF, at 100 ng/ml, potentiated by 25% the K⁺-evoked release of [³H]glutamate from hippocampal synaptosomes. The small effect of BDNF on [³H]glutamate release correlated with a modest increase in phospholipase Cγ (PLCγ) phosphorylation, and with the lack of effect of BDNF on extracellular-signal regulated kinase (ERK) and Akt phosphorylation. Immunocytochemistry studies demonstrated that only about one-third of glutamatergic synaptosomes were positive for TrkB immunoreactivity. Furthermore, biotinylation and subsynaptic fractionation studies showed that only one-fourth of total full-length TrkB was present at the plasma membrane, evenly distributed between the presynaptic active zone and the postsynaptic density. These results indicate that BDNF modulates synaptic transmission presynaptically in a small subset of hippocampal glutamatergic synapses that contain TrkB and that express the receptor on the plasma membrane.

Key words: BDNF; hippocampal synaptosomes; presynaptic TrkB; rat

Neurotrophins are recognized currently as important modulators of synaptic plasticity in central and peripheral nervous systems in addition to their role in neuronal differentiation and survival (Schuman, 1999; Poo, 2001). Particular attention has been given to the hippocampus because it is a prominent site of expression of BDNF and NT-3 and their receptors (Ernfors et al., 1990; Klein et al., 1990; Lamballe et al., 1991). The physiological actions of BDNF, a well established modulator of hippocampal synaptic transmission, are mediated by the high-affinity receptor tyrosine kinase TrkB, and the low affinity pan-neurotrophin receptor p75 (Chao, 2003). BDNF binding to TrkB leads to the activation of the ERK, the phosphatidylinositol 3-kinase (PI3-K) and the PLCγ pathways, which transduce most of the cellular responses to BDNF (Huang and Reichardt, 2003).

Studies in hippocampal primary cultures show that exogenously applied BDNF enhances the evoked and spontaneous excitatory synaptic transmission (Lessmann et al., 1994; Levine et al., 1995). Although a postsynaptic contribution to this effect has been suggested (Levine et al., 1995, 1998), a predominant presynaptic action has been demonstrated convincingly in cultured hippocampal neurons (Lessmann and Heumann, 1998; Li et al., 1998a,b; Berninger et al., 1999; Schinder et al., 2000). A recent study showed that early presynaptic and late postsynaptic components contribute independently to BDNF-induced synaptic plasticity in dissociated cultures of hippocampal neurons (Alder et al., 2005).

In contrast, in hippocampal preparations from mature animals, the effect of BDNF on excitatory synaptic transmission remains a matter of controversy. An early
study using acutely dissociated hippocampal slices showed that superfusion with BDNF induces a long lasting potentiation of excitatory synaptic transmission in the CA1 area, acting at a presynaptic locus (Kang and Schuman, 1995). Other groups have been unable to reproduce these results (Figurov et al., 1996; Patterson et al., 1996; Tanaka et al., 1997; Frerking et al., 1998; Gottschalk et al., 1998). It has been suggested that low penetration of BDNF into the slice tissue due to different rates of neurotrophin application is the underlying reason for this discrepancy (Kang et al., 1996). Nonetheless, superfusion rates cannot solely account for such inconsistencies because a lack of BDNF effect was also observed in studies using rapid superfusion rates (Tanaka et al., 1997; Frerking et al., 1998). A lasting enhancement of synaptic transmission by BDNF in the dentate gyrus "in vivo" was also reported (Messiaud et al., 1998), but this was demonstrated to occur, at least partially, through postsynaptic mechanisms (Messiaud et al., 2002; Ying et al., 2002). Accordingly, stimulation of dentate gyrus synaptosomes with BDNF did not affect KCl-evoked glutamate release. In this study, however, a synergistic effect was observed between the neurotrophin and (1S,3R)ACPD [(1S,3R)-1-aminocyclopentane-1,3-dicarboxylic acid], a metabotropic glutamate receptor agonist, in the potentiation of depolarization-evoked glutamate release (Gooney and Lynch, 2001).

BDNF has been implicated more convincingly in hippocampal long-term potentiation (LTP). BDNF knock-out mice show severe impairments in LTP in the CA1 region that can be rescued by application of exogenous BDNF or by virus-mediated BDNF gene transfer (Korte et al., 1996; Patterson et al., 1996). Scavenging of endogenous BDNF or genetically engineered reduction of TrkB levels also leads to deficits in hippocampal LTP (Figurov et al., 1996; Minichiello et al., 1999; Xu et al., 2000). It has been suggested that BDNF plays a permissive role in this event by maintaining an appropriate number of docked vesicles at the active zone, thus preventing synaptic fatigue (Figurov et al., 1996; Pozzo-Miller et al., 1999; Tartaglia et al., 2001). An instructive role for BDNF in LTP induction has also been supported by recent reports (Kossel et al., 2001). Accordingly, stimulation of dentate gyrus synaptosomes with BDNF did not affect KCl-evoked glutamate release. In this study, however, a synergistic effect was observed between the neurotrophin and (1S,3R)ACPD [(1S,3R)-1-aminocyclopentane-1,3-dicarboxylic acid], a metabotropic glutamate receptor agonist, in the potentiation of depolarization-evoked glutamate release (Gooney and Lynch, 2001).

**MATERIALS AND METHODS**

**Materials**

Fatty acid free bovine serum albumin (BSA) and K-252a were obtained from Calbiochem-Novabiochem Intl. (La Jolla, CA). Reagents used in immunoblotting experiments were purchased from Bio-Rad (Hercules, CA). [3H]Glutamate (specific activity, 45 Ci/mmol), polyvinylidene difluoride (PVDF) membranes, alkaline phosphatase-linked secondary antibodies, enhanced chemiluminescence (ECL) reagent, and Percoll were obtained from Amersham Biosciences (Buckinghamshire, England). The rabbit polyclonal antibody against dually phosphorylated ERK was purchased from Promega (Madison, WI). The mouse anti-TrkB antibody was from BD Biosciences Europe (Erembodegem, Belgium), rat anti-TrkB was from Santa Cruz Biotechnology (Santa Cruz, CA), and mouse anti-Trk (E7) was from ZyMed (Carlsbad, CA). The rabbit anti-phospho-Akt (Ser 473), anti-phospho-PLCγ (Tyr 783), and anti-phospho-Trk (Tyr 490) antibodies were from Cell Signaling Technology (Beverly, MA). Anti-VGluT1 and anti-VGlut2 guinea pig antibodies were obtained from Chemicon (Temecula, CA). Rabbit anti-syntaxin 1A was a gift by Dr. Juan Blasi (Universitat de Barcelona, Barcelona, Spain). The Alexa Fluor secondary antibodies and the Prolong Antifade mounting medium were purchased from Molecular Probes Europe BV (Leiden, The Netherlands). EZ-link sulfo-NHS-SS-biotin and UltraLink Plus immobilized streptavidin were obtained from Pierce (Rockford, IL). The Microcon YM-3 centrifugal filter device, used to concentrate protein samples, was from Millipore Corporation, (Bedford, MA). BDNF was granted by Regeneron Pharmaceuticals Inc. (Tarrytown, NY). All other reagents were from Sigma Chemical Co. (St. Louis, MO) or from Merck KGaA (Darmstadt, Germany).

**Isolation of Crude (P2) and Purified Hippocampal Synaptosomal Fractions**

The crude synaptosomal P2 fraction from male Wistar rat hippocampi was isolated as described elsewhere (McMahon et al., 1992; Pereira et al., 2002). Briefly, hippocampi of 6- to 8-week-old animals were dissected and homogenized (5%, w/v) in 0.32 M sucrose, 10 mM HEPES, pH 7.4 (sucrose buffer), using a Thomas B homogenizer. The suspension was centrifuged at 3,000 x gmax for 2 min, and the supernatants were spun at 14,600 x gmax for 12 min. The upper white layer of the pellet (P2) was removed and resuspended in sucrose buffer. Alternatively, a purified hippocampal synaptosomal suspension was isolated using the Percoll method described elsewhere (Dunkley et al., 1986) with some modifications (Pereira et al., 2002). The whole P2 pellet was resuspended in sucrose buffer and layered on top of Percoll discontinuous gradients (23%, 10%, and 3% Percoll in sucrose buffer for immunoblots and biotinylation experiments, or in 0.32 M sucrose, 1 mM EDTA, and 0.25 mM dithiothreitol for immunocytochemistry). After centrifugation at 36,500 x gmax for 5 min (or 25,000 x gav, for 11 min, for immunocytochemistry experiments) the purified synaptosomal fraction was removed (23%/10% Percoll interface) and resuspended in 15 vol of sucrose buffer or HEPES buffer (in mM, 140 NaCl, 5 KCl, 5 NaHCO3, 1.2 NaH2PO4, 1.2 MgCl2, 10 glucose, 10 HEPES, pH 7.4, for immunocytochemistry). Percoll was removed by spinning twice at 30,500 x gmax for 20 min (or once at 20,000 x gav, for 11 min, in the case of the immunocytochemistry experiments). The alternative protocol used for the immunocytochemistry experiments allowed us to obtain purified synaptosomes less contaminated with postsynaptic structures. The whole procedure was carried out at 0–4°C.
Hippocampal Cell Culture

Hippocampal primary neurons were isolated and maintained as described previously (Almeida et al., 2005). Briefly, hippocampi from E18–E19 Wistar rat embryos were dissected in Ca²⁺- and Mg²⁺-free Hank’s balanced salt solution (HBSS; in mM, 137 NaCl, 5.36 KCl, 4.16 NaHCO₃, 0.44 KH₂PO₄, 0.34 Na₃HPO₄·2H₂O, 5 glucose, supplemented with 1 mM sodium pyruvate, 10 mM HEPES, and 0.001% phenol red, pH 7.4), and incubated with 0.9 mg/ml trypsin, for 15 min at 37°C, in HBSS containing 0.5 mg/ml deoxyribonuclease I. Cells were washed in HBSS with 10% fetal bovine serum (FBS) and mechanically dissociated with a pipette in HBSS. Hippocampal neurons were maintained in serum-free Neurobasal medium supplemented with B27 supplement, 0.5 mM glutamine, 0.12 mg/ml gentamycin, and 25 μM glutamate, at a density of 90 × 10³ cells/cm², and kept for 7–8 days at 37°C in a humidified incubator with 5% CO₂/95% air.

[^H]Glutamate Release

The release of [³H]glutamate was carried out as described previously (Rojahigues et al., 2005). In short, P₂ synaptosomes were washed once with KHR medium (composed of the following [in mM]: 140 NaCl, 1 EDTA, 5 KCl, 5 glucose, and 10 HEPES, pH 7.4), and resuspended in a Na⁺-salt solution (containing [in mM]: 124 NaCl, 3 KCl, 1.25 NaH₂PO₄, 25 NaHCO₃, 2 MgSO₄, 2 CaCl₂, and 10 glucose, pH 7.4), which was gassed with a 95% O₂ and 5% CO₂ mixture. The nerve terminals were equilibrated at 37°C for 10 min, loaded with 0.2 μM [³H]glutamate for 5 min at 37°C, washed, layered over Whatman GF/C filters, and superfused (flow rate, 0.8 ml/min) with Na⁺-salt solution for 20 min before starting collection of the superfusate. The synaptosomes were stimulated with 20 mM KCl (isosmolar substitution of NaCl by KCl in the salt solution) for 30 sec, at 3 and 9 min after starting sample collection (S₁ and S₂), triggering a release of tritium in a Ca²⁺-dependent manner that is mostly glutamate (Lopes et al., 2002). When the effect of BDNF was tested the neurotrophin was added 2 min before S₂ onward, and its effect was quantified by the modification of the S₂/S₁ ratio versus control (i.e., absence of BDNF).

Immunoblotting

Purified synaptosomes (2 mg protein/ml) were pre-incubated for 40 min at 37°C in incubation medium, followed by incubation in reaction medium at 37°C for 5 min (control). BDNF was added for 1, 4, or 30 min. The reaction was stopped by adding 2× sample buffer (100 mM Tris, 100 mM glycine, 4% sodium dodecyl sulfate [SDS], 8% β-mercaptoethanol, 8 M urea, 3 mM sodium orthovanadate, and 0.001% bromophenol blue), and heating the samples for 5 min at 95°C. Hippocampal neurons in culture were stimulated for 15 or 30 min with BDNF before ending the reaction by washing in ice-cold PBS/Ca²⁺/Mg²⁺-salt solution for 5 min at 37°C, and lysing the cells with supplemented RIPA buffer (150 mM NaCl, 50 mM Tris, 5 mM EGTA, 1% Triton, 0.5% deoxycholic acid [DOC], 0.1% SDS, pH 7.5, supplemented with protease inhibitors [1 μg/ml chymostatin, leupeptin, antipain, and pepstatin, CLAP, and 100 μM PMSF] and 1 mM dithiothreitol [DTT]). After one freeze-thaw cycle, lysates were centrifuged at 16,100 × gmax during 10 min at 4°C, to remove solid debris, and denatured for 5 min at 95°C in 2X sample buffer (125 mM Tris, 100 mM glycine, 4% SDS, 200 mM DTT, 20% glycerol, 3 mM sodium orthovanadate, and 0.001% bromophenol blue). Equal amounts of protein (10–30 μg), as determined by the bicinchoninic acid (BCA) method (Smith et al., 1985), were separated by electrophoresis on 6 or 10% SDS-polyacrylamide gels (SDS-PAGE), and transferred electrophoretically to polyvinylidene difluoride (PVDF) membranes. These were blocked for 1 hr at room temperature, in Tris-buffered saline (137 mM NaCl, 20 mM Tris–HCl, pH 7.6) containing 0.1% Tween 20 (TBS–T) and 5% low fat milk. Incubation with the primary antibodies (anti-active ERK1/2 1:5,000, anti-phospho-Akt [Ser473] 1:1,000 and anti-phospho-Trk [Tyr 490] 1:1,000 in TBS–T 1% low fat milk; anti-phospho-PLCγ 1:750 in TBS–T 5% BSA) was carried out overnight at 4°C or for 1 hr at room temperature. After extensive washing, the membranes were incubated with an alkaline phosphatase-linked secondary antibody (1:20,000 in TBS–T 1% low fat milk). Protein immunoreactive bands were visualized by ECF on a Storm 860 Gel and Blot Imaging System (Amersham Biosciences), after incubation of the membranes with ECF reagent for 5 min.

Biotinylation Experiments

Plasma membrane synaptosomal proteins were biotinylated essentially as described previously (Gomes et al., 2004). Synaptosomes purified by Percoll gradients (2 mg protein/ml) were pre-incubated for 40 min at 37°C in incubation medium. After a 5-min incubation in reaction medium at 37°C, synaptosomes were pelleted and placed on ice. The nerve terminals were resuspended in ice-cold PBS/Ca²⁺/Mg²⁺-salt solution containing 1 mg/ml sulfo-NHS-SS-biotin, and incubated for 30 min at 4°C. Synaptosomes were washed twice in PBS/Ca²⁺/Mg²⁺ with 100 mM glycine to remove the excess of biotin, and washed once again in PBS/Ca²⁺/Mg²⁺. Supplemented RIPA buffer was used to lyse the nerve terminals following the same procedure described above for hippocampal neurons. The lysates were precipitated twice with UltraLink Plus immobilized streptavidin beads for 2 hr at 4°C, to confirm that all biotinylated protein was precipitated. Streptavidin precipitates were washed with RIPA buffer and eluted with sample buffer (62.5 mM Tris, 50 mM glycine, 2% SDS, 100 mM DTT, 10% glycerol, 1.5 mM sodium orthovanadate and 0.0005% bromophenol blue). The supernatants were concentrated by centrifugation at 13,500 × gmax for 1 hr 45 min at 4°C in Microcon YM-3 centrifugal filter devices, or left in the original concentration. After denaturation, the whole volume of the precipitates and the concentrated supernatant, or one-eighth of the total volume of the supernatant in the original concentration, were loaded and separated in 6% SDS-PAGE and immunoblotted as described above with the mouse anti-TrkB antibody (1:750 in TBS–T 1% low fat milk). The use of different concentrations of the supernatant allowed us to confirm the reliability of the quantification method.

Subsynaptic Fractionation

The separation of the presynaptic active zone, postsynaptic density, and non-synaptic fractions from hippocampal
nerve terminals was carried out essentially as described initially by Phillips et al. (2001). Briefly, purified synaptosomes were diluted 1:10 in cold 0.1 mM CaCl₂. An equal volume of 2%, 3% solubilization buffer (2% Triton X-100, 40 mM Tris, pH 6.0) was added, and after 30 min of incubation on ice the resulting insoluble synaptic junctions were pelleted by spinning at 100,000 g for 30 min at 4°C. The supernatant (extrasynaptic fraction) was decanted and proteins were precipitated with 6 vol of acetone at −20°C, and recovered by centrifugation at 18,000 g for 30 min at −15°C. The insoluble pellet was resuspended and incubated for 30 min in 10 vol of cold solubilization buffer at pH 8.0 to promote the dissociation of the extracellular matrix and hence the separation of the presynaptic active zone from the postsynaptic density. A centrifugation step precipitated the postsynaptic density, which is insoluble at 1% Triton X-100. The solubilized presynaptic active zone proteins, present in the supernatant, were precipitated and recovered as described for the extrasynaptic fraction. All precipitated fractions were solubilized in 5% SDS and the protein concentration was determined by the BCA method (Smith et al., 1985). The samples were denatured with 2× sample buffer and stored at −20°C. The protease inhibitor PMSF was present in all extraction steps. Samples were probed with the rabbit anti-TrkB (1:500) using the immunoblotting procedure described previously.

Immunocytochemistry

Percoll purified synaptosomes were resuspended in HEPES buffer, allowed to adhere to poly-L-lysine-coated coverslips and processed for immunocytochemistry as described previously (Diaz-Hernandez et al., 2002). Briefly, synaptosomes were fixed with 4% parafomaldehyde and incubated with 0.1% Triton X-100, 3% BSA, and 5% calf serum in PBS, for 1 hr at room temperature. The coverslips were then washed and incubated with the primary antibodies in PBS with 3% BSA and 5% normal rat serum (rabbit anti-TrkB 1:500, mouse anti-TrkB 1:50, guinea pig anti-VGluT1 or anti-VGluT2 1:5,000, mouse anti-synaptophysin 1:100, and rabbit anti-syntaxin 1A 1:200). After washing with 3% BSA in PBS, the synaptosomes were incubated with Alexa 488 anti-rabbit, Alexa 594 anti-mouse, and Alexa 594 anti-guinea pig secondary antibodies. After the last washing steps, coverslips were mounted with Prolong Antifade mounting medium and visualized using a Zeiss Axiovert 200 inverted microscope equipped with a cooled CCD camera. The resulting images were analyzed with MetaFluor 4.0 software.

Statistical Analysis

Results are presented as means ± SEM of the indicated number of experiments. Statistical significance was determined using two-tailed t-test or one-way ANOVA followed by Newman-Keuls or Dunnett post-tests, as indicated.

RESULTS

BDNF Stimulates [3H]Glutamate Release From Hippocampal Nerve Terminals

A putative role for BDNF in the modulation of glutamate release from adult rat hippocampal synaptosomes was studied using superfused nerve terminals loaded previously with [3H]glutamate. Under these conditions, depolarization with 20 mM KCl for 30 sec was previously shown to induce Ca²⁺-dependent release of [3H]glutamate that represented about 90% of the total tritium released, as determined by HPLC (Lopes et al., 2002). Two consecutive stimulations with 20 mM KCl (S₁ and S₂), separated by 6 min, induced the release of about the same amount of glutamate, with an S₂/S₁ ratio.
of 0.92 ± 0.03 (n = 4). When synaptosomes were superfused with BDNF (100 ng/ml) for 2 min before the second depolarization pulse with KCl (S2) there was a significant (P < 0.05) increase in the evoked release of [3H]glutamate, to 125.6 ± 6.0% of the control (Fig. 1). These results indicate that BDNF acts presynaptically to modulate glutamate release.

**BDNF Activates TrkB But Does Not Significantly Activate ERK or Akt in Hippocampal Nerve Terminals**

To confirm the presence of BDNF-sensitive Trk receptors in hippocampal synaptosomes, denatured samples of Percoll purified nerve terminals, incubated with BDNF for 1, 4, or 30 min, were probed with anti-phospho-Trk (Tyr 490) antibody, which recognizes the activated form of Trk receptors (Fig. 2). BDNF, at the concentration of 100 ng/ml, increased TrkB phosphorylation by about four-fold after just 1 min of incubation, and to more than six-fold after 4 and 30 min. These results show that TrkB can be phosphorylated and hence activated in response to BDNF in hippocampal nerve terminals.

We next investigated whether TrkB phosphorylation in response to BDNF resulted in the activation of downstream signaling pathways. BDNF-stimulated purified nerve terminals were probed for their content on the phosphorylated forms of ERK1/2, Akt and PLCγ (Fig. 3). A certain level of ERK phosphorylation was found for both isoforms (ERK1/p44 and ERK2/p42) in control conditions (Fig. 3A), using an antibody against the dually phosphorylated (presumably active) form of ERK, as previously demonstrated in hippocampal synaptosomes (Pereira et al., 2002). BDNF, at 100 ng/ml, was unable to significantly increase ERK1/2 phosphorylation (Fig. 3B). Quantitative results are shown only for the ERK2 isoform because phosphorylation of both isoforms varied in a similar manner. Akt phosphorylation, which occurs downstream of PI3-K activation, was not significantly affected by incubating nerve terminals with BDNF for several durations, as shown in the repre-
sentative blot (Fig. 3A) and in the quantitative analysis plot (Fig. 3D).

In contrast to the lack of effect of BDNF on ERK and Akt signaling pathways, PLCγ phosphorylation increased approximately two-fold after a 4-min incubation of hippocampal synaptosomes with 100 ng/ml BDNF (Fig. 3A, C; BDNF 30 min). BDNF-induced PLCγ activation in hippocampal synaptosomes was completely abolished by the Trk kinase inhibitor K-252a, at the concentration of 200 nM (Berg et al., 1992; Tapley et al., 1992) (Fig. 4A, B). This suggests that PLCγ phosphorylation in response to BDNF was indeed mediated by the TrkB receptor.

To confirm that the BDNF used in these studies was able to activate all TrkB initiated signaling pathways in a different system, we probed BDNF-stimulated hippocampal neuron cultures for pERK, pAkt, and pPLCγ. BDNF induced Akt phosphorylation (approximately 5- and 4-fold, for 15 and 30 min stimulation, respectively; Fig. 5A, C) and massive phosphorylation of ERK (approximately 25- and 15-fold for 15 and 30 min stimulation, respectively; Fig. 5A, B) in cultured hippocampal neurons. In the same cell culture, PLCγ phosphorylation was increased by eight- and six-fold, after 15- and 30-min incubations with BDNF, respectively (Fig. 5A, D). These results confirm that the BDNF used in this study was capable of fully inducing the activation of the ERK,
Akt and PLCγ pathways in cultured hippocampal neurons. The comparison of the amplitude of the BDNF-induced activation of these signaling pathways in cultured neurons and purified synaptosomes suggests that the effects of BDNF are minimal in the overall population of hippocampal nerve terminals, correlating with the small effect on glutamate release in nerve endings.

**TrkB Is Absent in More Than Two-Thirds of Adult Hippocampal Glutamatergic Nerve Terminals**

The small effect of BDNF on KCl-evoked glutamate release, and in stimulating TrkB downstream signaling pathways in hippocampal synaptosomes lead us to examine the percentage of nerve terminals that are endowed with TrkB in the adult hippocampus. Synaptosomes were plated on poly-L-lysine-coated coverslips and processed for immunocytochemistry as described in Materials and Methods. Antibodies against synaptophysin (Fig. 6) and syntaxin 1A (data not shown), presynaptic vesicle and plasma membrane proteins, respectively, were used as presynaptic markers. TrkB receptors were labeled with two different anti-TrkB antibodies that recognize the full-length and the truncated forms of the receptor (Fig. 6 and data not shown). As shown in Figure 6 A–C, rabbit anti-TrkB and mouse anti-synaptophysin staining co-localized partially (arrowheads in Fig. 6C). However, a quantification of these images showed that approximately 70% of synaptophysin-labeled structures lacked TrkB labeling (Table I). Similar results were obtained with rabbit anti-syntaxin 1A and mouse anti-TrkB antibodies (data not shown). These data suggest that only about one-third of presynaptic terminals in the adult rat hippocampus are endowed with TrkB receptors.

It is important to realize that >90% of TrkB-labeled structures were also synaptophysin-positive (Fig. 6A–C, Table I). This suggests that this purified synaptosomal preparation is mostly devoid of postsynaptic contaminating structures, or that TrkB receptors are confined to nerve terminals at the synapse. The former hypothesis seems...
likely because staining with an anti–PSD-95 antibody did not yield any significant signal (data not shown).

We next investigated the presence of TrkB in glutamatergic presynaptic terminals. The VGluT1 and VGluT2 isoforms of vesicular glutamate transporters have been used as glutamatergic nerve terminal markers because: 1) all glutamatergic synapses, possess either VGluT1 or VGluT2 (Fremeau et al., 2001); 2) the presence of VGluT1 or VGluT2 in non-glutamatergic neurons is sufficient to define a glutamatergic phenotype (Takamori et al., 2000, 2001); and 3) VGluT1 and VGluT2 are predominantly located at nerve terminals, in synaptic vesicles, with few or no overlap (Herzog et al., 2001).

As expected, VGluT1 and VGluT2 strongly co-localized with synaptophysin (Fig. 6D–I, arrowheads). Moreover, about 35% and 15% of synaptophysin-positive structures were VGluT1 and VGluT2-positive, respectively (Fig. 6F,I, Table I), confirming that most hippocampal glutamatergic nerve terminals express VGluT1. The amount of synaptophysin-positive structures containing VGluT1 was not significantly different from the amount of synaptophysin-positive structures containing either VGluT1 or VGluT2 (approximately 40%; Table I; P > 0.05, as determined by one-way ANOVA with Bonferroni test). These results suggest that approximately 40% of adult hippocampal nerve terminals are glutamatergic and that a fraction of these glutamatergic terminals express both VGluT1 and VGluT2.

Only about one-third of VGluT1-containing terminals and one-fourth of VGluT2-immunoreactive ones were TrkB-positive (Fig. 6J–O, Table I). The results shown in Figure 6J–O were obtained using the rabbit anti-TrkB antibody and they were reproduced using two other anti-Trk antibodies (the mouse anti-Trk [E7] and the mouse anti-TrkB; data not shown). When all glutamatergic terminals were stained by using anti-VGluT1 and anti-VGluT2 antibodies, simultaneously, we observed that TrkB was absent from the postsynaptic density (Fig. 7A,B). A small 10% fraction of the total truncated isoform was also present at the presynaptic active zone (Fig. 7A,B).

The isolation of subsynaptic fractions showed that the majority of TrkB receptors are excluded from the synaptic junction, but it did not clarify whether they are present at the plasma membrane, away from the active zone, or at intracellular locations. To address this question, proteins located at the plasma membrane were tagged with biotin and precipitated with streptavidin beads. Biotinylated samples were precipitated twice to test for the efficiency of the process. Both precipitates and supernatants were probed for their content in TrkB. Biotinylated proteins from the first precipitation contained the full-length and truncated forms of the receptor (Fig. 7C). The second precipitation did not significantly recover any of the TrkB isoforms, confirming the efficiency of the first streptavidin precipitation (Fig. 7C). The immunoreactivity showed in the supernatant lane for p145 and p95 TrkB corresponds to one-eighth of the total immunoreactivity present in the supernatant because only one-eighth of the total volume was probed (Fig. 7C). In some cases, the supernatant samples were concentrated by centrifugation on centrifugal filter devices so that the total volume of the supernatant could be probed. This allowed us to test for the reliability of the quantification method. We found that only about 25% of total full-length TrkB present in this synaptosomal preparation was biotinylated (Fig. 7D). However, the percentage of biotinylated truncated TrkB was significantly higher than biotinylated p145, reaching nearly 50% (Fig. 7D).

These data indicate that the majority of TrkB present at the Percoll purified hippocampal nerve terminal preparation is located intracellularly.

**Full-Length TrkB Receptors Are Distributed in Pre-, Post-, and Extrasynaptic Sites and Are Mostly Located Intracellularly**

We further investigated the expression and distribution of TrkB at adult hippocampal synapses using two approaches. First, we followed a fractionation procedure described previously that allows the separation of proteins from the presynaptic active zone and the postsynaptic density from proteins present in other parts of the synapse. Second, we determined the percentage of TrkB receptors located at the plasma membrane and at intracellular locations in hippocampal synaptosomes, by tagging extracellular proteins with biotin.

Subsynaptic fractionation was carried out by extracting synaptosomes sequentially with 1% Triton X-100 at pH 6.0 followed by pH 8.0. Triton X-100 solubilizes most synaposomal components with the exception of the “synaptic junction,” which contains the presynaptic active zone, the postsynaptic density, and interlinked transmembrane adhesion molecules. The presynaptic active zone is then solubilized by increasing the pH to 8.0 (Materials and Methods; Phillips et al., 2001). This procedure has been shown previously to separate pre-, post-, and extrasynaptic markers with over 90% efficiency (Pinheiro et al., 2003; Rebola et al., 2003). Full-length (p145) and truncated TrkB (p95) showed a differential distribution among the three subsynaptic fractions (Fig. 7A,B). The majority of both TrkB isoforms was found in the extrasynaptic fraction, which includes intracellular and plasma membrane proteins that are excluded from the synaptic junction. However, approximately 35% of full length TrkB was evenly distributed between the presynaptic active zone and the postsynaptic density, whereas truncated TrkB was absent from the postsynaptic density (Fig. 7A,B). A small 10% fraction of the total truncated isoform was also present at the presynaptic active zone (Fig. 7A,B).

The isolation of subsynaptic fractions showed that the majority of TrkB receptors are excluded from the synaptic junction, but it did not clarify whether they are present at the plasma membrane, away from the active zone, or at intracellular locations. To address this question, proteins located at the plasma membrane were tagged with biotin and precipitated with streptavidin beads. Biotinylated samples were precipitated twice to test for the efficiency of the process. Both precipitates and supernatants were probed for their content in TrkB. Biotinylated proteins from the first precipitation contained the full-length and truncated forms of the receptor (Fig. 7C). The second precipitation did not significantly recover any of the TrkB isoforms, confirming the efficiency of the first streptavidin precipitation (Fig. 7C). The immunoreactivity showed in the supernatant lane for p145 and p95 TrkB corresponds to one-eighth of the total immunoreactivity present in the supernatant because only one-eighth of the total volume was probed (Fig. 7C). In some cases, the supernatant samples were concentrated by centrifugation on centrifugal filter devices so that the total volume of the supernatant could be probed. This allowed us to test for the reliability of the quantification method. We found that only about 25% of total full-length TrkB present in this synaptosomal preparation was biotinylated (Fig. 7D). However, the percentage of biotinylated truncated TrkB was significantly higher than biotinylated p145, reaching nearly 50% (Fig. 7D).

These data indicate that the majority of TrkB present at the Percoll purified hippocampal nerve terminal preparation is located intracellularly.
DISCUSSION

We present evidence supporting the presence of TrkB receptors in only about one-third of glutamatergic hippocampal nerve terminals from adult rats. This correlates with the small effect of BDNF on the phosphorylation of PLCγ and on KCl-evoked glutamate release from the whole population of hippocampal synaptosomes. Furthermore, only 25% of full-length TrkB present in this synaptosomal preparation was located at the plasma membrane, evenly distributed among the presynaptic active zone (pre), postsynaptic density (post), and extrasynaptic (extra) fractions. These fractions were immunoblotted and probed with a rabbit anti-TrkB antibody that recognizes the full-length (p145) and the truncated (p95) form of the receptor. A representative membrane is shown in (A) whereas (B) depicts the quantification of three independent experiments. Data is presented as mean % of total p145 or p95 TrkB immunoreactivity ± SEM. C,D: Purified hippocampal synaptosomes were incubated with sulfo-NHS-SS-biotin to tag plasma membrane proteins, and precipitated twice with streptavidin beads (Materials and Methods). C: Representative immunoblot showing p145 and p95 TrkB present in the total volume of the first (PP #1) and the second (PP #2) precipitates, and in one-eighth of the total supernatant (S/8). D: Quantification of seven independent experiments representing the mean % of biotinylated TrkB ± SEM. Each experiment was carried out using a different synaptosomal preparation. Total TrkB was calculated by adding the value for precipitated TrkB to the value for supernatant TrkB multiplied by 8. In some experiments, the total supernatant was probed, after concentrating the samples. In this case, total TrkB was calculated simply by adding precipitated and supernatant TrkB values.

Fig. 7. Full-length TrkB localization at the adult hippocampal synapse: pre- and postsynaptic, but mostly intracellular. A,B: Subsynaptic fractionation of purified hippocampal synaptosomes was carried out as described in Materials and Methods to obtain presynaptic active zone (pre), postsynaptic density (post), and extrasynaptic (extra) fractions. These fractions were immunoblotted and probed with a rabbit anti-TrkB antibody that recognizes the full-length (p145) and the truncated (p95) form of the receptor. A representative membrane is shown in (A) whereas (B) depicts the quantification of three independent experiments. Data is presented as mean % of total p145 or p95 TrkB immunoreactivity ± SEM. C,D: Purified hippocampal synaptosomes were incubated with sulfo-NHS-SS-biotin to tag plasma membrane proteins, and precipitated twice with streptavidin beads (Materials and Methods). C: Representative immunoblot showing p145 and p95 TrkB present in the total volume of the first (PP #1) and the second (PP #2) precipitates, and in one-eighth of the total supernatant (S/8). D: Quantification of seven independent experiments representing the mean % of biotinylated TrkB ± SEM. Each experiment was carried out using a different synaptosomal preparation. Total TrkB was calculated by adding the value for precipitated TrkB to the value for supernatant TrkB multiplied by 8. In some experiments, the total supernatant was probed, after concentrating the samples. In this case, total TrkB was calculated simply by adding precipitated and supernatant TrkB values.
1999). These results do not clarify, though, the percentage of nerve terminals that express p145 TrkB at the surface. Nevertheless, these data suggest that, within the small fraction of TrkB-positive glutamergic nerve terminals, the percentage of terminals capable of responding to BDNF may be even smaller due to the small percentage of TrkB receptors present at the plasma membrane. The amplitude of the responses to BDNF in vivo may change depending on the recent history of the terminal because plasma membrane depolarization and cAMP elevation rapidly increase the amount of TrkB receptors associated with the plasma membrane of CNS neurons (Meyer-Franke et al., 1998).

An interesting difference in the location of full length and truncated TrkB receptors resides in their subsynaptic distribution. Although approximately 35% of p145 TrkB receptors were evenly distributed between the presynaptic active zone and the postsynaptic density, the truncated isoform was absent from the postsynaptic density and only 10% was present at the presynaptic active zone (Fig. 7). Because only about 25% of full-length TrkB was present at the plasma membrane, this suggests that all extrasynaptic p145 TrkB is intracellular. About half of p95 TrkB was at the plasma membrane indicating that a significant fraction of the extrasynaptic truncated isoform is located there. This confinement of the catalytically active TrkB receptor to the active zone is very interesting considering the known effects of BDNF on synaptic transmission and plasticity discussed below. The absence of the truncated receptor at the postsynaptic density, reported previously in adult rat brain (Kryl et al., 1999; Xu et al., 2000), raises the question of the precise function of p95 TrkB: does it work simply as a BDNF scavenger, or does it mediate a synaptic response independently of p145 TrkB, as suggested for other cellular outcomes (Baxter et al., 1997; Yacoubian and Lo, 2000; Rose et al., 2003), which is dependent on its specific location?

Application of BDNF to isolated hippocampal nerve terminals increased TrkB phosphorylation, showing that TrkB receptors located at the synapticosomal plasma membrane can be activated by its ligand. The lack of effect of BDNF on ERK and Akt phosphorylation in the overall nerve terminal population is probably due to the reduced number of terminals that express TrkB at the plasma membrane. Thus, the eventual ERK and Akt activation triggered by TrkB in a limited number of terminals was probably undetectable above the basal activation of these molecules in the whole population of terminals. BDNF was still able to significantly stimulate PLCγ phosphorylation, which is interesting because PLCγ is involved in BDNF-induced potentiation of depolarization-evoked exocytotic glutamate release in cultured cortical neurons (Matsumoto et al., 2001). This suggests that the basal phosphorylation of this protein is sufficiently low to allow the detection of an increase in phosphorylation of a small percentage of the total PLCγ.

The small fraction of glutamatergic nerve terminals that are endowed with TrkB at the plasma membrane, accessible to its specific ligands, accounts for the small effect of BDNF on the average [3H]glutamate release (about 25% increase) from a population of hippocampal synaptosomes. This effect of BDNF was not observed in a previous study, where the effect of the neurotrophin on KCl-evoked release of endogenous glutamate from dentate gyrus synaptosomes was investigated, possibly due to the lower sensitivity of the method used. In this case, however, BDNF was shown to act synergistically with the metabotropic glutamate receptor agonist (1S,3R)ACPD to potentiate KCl-evoked glutamate release, to a small extent (Gooney and Lynch, 2001). These findings and our own results contrast with the large effect of BDNF on [3H]glutamate release from hippocampal synaptosomes isolated from 3-week-old rats, where the neurotrophin potentiated neurotransmitter release evoked by KCl-depolarization to about 400% of the control (Canas et al., 2004). It would be interesting to know whether the percentage of TrkB-positive glutamatergic synaptosomes in developing rats, to determine whether a change in the glutamatergic nerve terminals expressing TrkB at the plasma membrane may account for the observed differences.

BDNF was also shown to potentiate 4-AP-evoked glutamate release from cerebrocortical synaptosomes in a synapsin I/II-dependent manner, probably by a mechanism involving ERK (Jovanovic et al., 2000; but see also Pereira et al., 2002). Forebrain synaptosomes of TrkB (+/-) mice show reduced levels of Ca2+-dependent neurotransmitter release in response to K+-depolarization (Carmona et al., 2003). This suggests that TrkB receptors are also present in the forebrain and cerebral cortex, where they modulate glutamate release.

BDNF was also shown to induce a long-lasting potentiation of evoked field excitatory postsynaptic potentials (EPSPs) in the CA1 region by acting presynaptically (Kang and Schuman, 1995), an effect that has not been confirmed by other laboratories (Figurov et al., 1996; Patterson et al., 1996; Tanaka et al., 1997; Frerking et al., 1998; Gottschalk et al., 1998). Although field EPSPs have the contribution of more than one synapse, based on the low number of TrkB-positive glutamatergic terminals demonstrated, one would predict a certain amount of failure to occur in BDNF-induced synaptic potentiation in this system. Therefore, our findings rather support the results by others showing an increase in field EPSPs after BDNF application in only 1 of 11 experiments (Frerking et al., 1998).

Several reports demonstrate that the involvement of BDNF in Schaffer collateral-CA1 synaptic LTP is at least partially achieved through presynaptic modifications, such as the reduction of synaptic fatigue by increasing the number of docked vesicles at the active zone (Figurov et al., 1996; Pozzo-Miller et al., 1999; Tyler and Pozzo-Miller 2001; Xu et al., 2000). How does this correlate with the small percentage of glutamatergic terminals that express TrkB at the plasma membrane? A putative increase in surface TrkB could be achieved after LTP-inducing high frequency stimulation, similarly to what was described for cultured hippocampal neurons (Du et al., 2000). A recruitment of TrkB recep-

Journal of Neuroscience Research DOI 10.1002/jnr
tors to presynaptic terminals, resulting in an augmented number of TrkB-positive glutamatergic terminals would be an interesting mechanism, although no evidence suggests it so far. Another possibility would be the involvement of postsynaptic TrkB receptors in the modulation of LTP by BDNF, as previously suggested (Tyler and Pozzo-Miller, 2001; Kovalchuk et al., 2002). This would predict the existence of a BDNF/TrkB-induced retrograde messenger that would carry out the presynaptic modifications attributed to BDNF during LTP. Selective genetic ablation of TrkB receptors in the CA1 region does not reduce LTP, however, suggesting that postsynaptic TrkB receptors are dispensable for LTP at the Schaffer collateral-CA1 synapses (Xu et al., 2000). Different LTP-inducing protocols are also modulated differentially by BDNF (Figurov et al., 1996; Kang et al., 1997; Patterson et al., 2001), and, therefore, the relative importance of presynaptic or postsynaptic TrkB receptors may vary accordingly.

Approximately half of TrkB-positive adult hippocampal nerve terminals were not stained with glutamatergic markers (Fig. 6, Table I). This suggests that non-glutamatergic synapses might also be possible targets for BDNF (Knip et al., 1994), and reduces GABA\textsubscript{A}-mediated inhibitory line release from adult hippocampal synaptosomes (Knip et al., 1994). This suggests it so far. Another possibility would be the involvement of postsynaptic TrkB receptors in the modulation of LTP by BDNF, as previously suggested (Tyler and Pozzo-Miller, 2001; Kovalchuk et al., 2002). This would predict the existence of a BDNF/TrkB-induced retrograde messenger that would carry out the presynaptic modifications attributed to BDNF during LTP. Selective genetic ablation of TrkB receptors in the CA1 region does not reduce LTP, however, suggesting that postsynaptic TrkB receptors are dispensable for LTP at the Schaffer collateral-CA1 synapses (Xu et al., 2000). Different LTP-inducing protocols are also modulated differentially by BDNF (Figurov et al., 1996; Kang et al., 1997; Patterson et al., 2001), and, therefore, the relative importance of presynaptic or postsynaptic TrkB receptors may vary accordingly.

In conclusion, our data show that only one-third of presynaptic glutamatergic nerve terminals express TrkB in the adult hippocampus. Within those terminals, an even lower percentage of this receptor is present at the plasma membrane, accessible to its ligands because 75% of full-length TrkB receptors are located intracellulary. This implies that BDNF does not modulate neurotransmitter release in the majority of these terminals, supporting a restricted synapse-specific action of BDNF in the modulation of glutamate release. Further studies will be required to relate TrkB synapse-specific expression with the state of synapse maturation and long term synaptic strengthening.

**ACKNOWLEDGMENTS**

We would like to express our gratitude to Regeneron Pharmaceuticals Inc. (Tarrytown, NY) for providing us with BDNF, and to Dr. J. Blasi for the syntaxin 1\(\alpha\) antibody. We would also like to thank E. Carvalho for excellent technical assistance.

**REFERENCES**


Gomes AR, Cunha P, Nunya M, Faro CJ, Huganir RL, Pires EV, Carvalho AL, Duarte CB. 2004. Metabotropic glutamate and dopamine receptors co-regulate AMPA receptor activity through activity-dependent mod-


